These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9506533)

  • 1. Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin.
    Schmidt M; Reiser P; Hills D; Gullick WJ; Wels W
    Int J Cancer; 1998 Mar; 75(6):878-84. PubMed ID: 9506533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors.
    Schmidt M; Maurer-Gebhard M; Groner B; Köhler G; Brochmann-Santos G; Wels W
    Oncogene; 1999 Mar; 18(9):1711-21. PubMed ID: 10208432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor.
    Schmidt M; Vakalopoulou E; Schneider DW; Wels W
    Br J Cancer; 1997; 75(11):1575-84. PubMed ID: 9184171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
    Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
    Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins.
    Wels W; Beerli R; Hellmann P; Schmidt M; Marte BM; Kornilova ES; Hekele A; Mendelsohn J; Groner B; Hynes NE
    Int J Cancer; 1995 Jan; 60(1):137-44. PubMed ID: 7814146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
    Michaelis M; Bliss J; Arnold SC; Hinsch N; Rothweiler F; Deubzer HE; Witt O; Langer K; Doerr HW; Wels WS; Cinatl J
    Clin Cancer Res; 2008 Oct; 14(20):6531-7. PubMed ID: 18927293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
    Lorimer IA; Wikstrand CJ; Batra SK; Bigner DD; Pastan I
    Clin Cancer Res; 1995 Aug; 1(8):859-64. PubMed ID: 9816055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha.
    Schmidt M; Wels W
    Br J Cancer; 1996 Sep; 74(6):853-62. PubMed ID: 8826849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.
    Lorimer IA; Keppler-Hafkemeyer A; Beers RA; Pegram CN; Bigner DD; Pastan I
    Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14815-20. PubMed ID: 8962138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor.
    Schmidt M; Hynes NE; Groner B; Wels W
    Int J Cancer; 1996 Feb; 65(4):538-46. PubMed ID: 8621240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of a single-chain variable fragment antibody recognizing type III mutant epidermal growth factor receptor.
    Nakayashiki N; Yoshikawa K; Nakamura K; Hanai N; Okamoto K; Okamoto S; Mizuno M; Wakabayashi T; Saga S; Yoshida J; Takahashi T
    Jpn J Cancer Res; 2000 Oct; 91(10):1035-43. PubMed ID: 11050475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
    Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
    Johns TG; Stockert E; Ritter G; Jungbluth AA; Huang HJ; Cavenee WK; Smyth FE; Hall CM; Watson N; Nice EC; Gullick WJ; Old LJ; Burgess AW; Scott AM
    Int J Cancer; 2002 Mar; 98(3):398-408. PubMed ID: 11920591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an EGFRvIII specific recombinant antibody.
    Gupta P; Han SY; Holgado-Madruga M; Mitra SS; Li G; Nitta RT; Wong AJ
    BMC Biotechnol; 2010 Oct; 10():72. PubMed ID: 20925961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line.
    Bruell D; Stöcker M; Huhn M; Redding N; Küpper M; Schumacher P; Paetz A; Bruns CJ; Haisma HJ; Fischer R; Finnern R; Barth S
    Int J Oncol; 2003 Oct; 23(4):1179-86. PubMed ID: 12964002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFRvIII as a promising target for antibody-based brain tumor therapy.
    Kuan CT; Wikstrand CJ; Bigner DD
    Brain Tumor Pathol; 2000; 17(2):71-8. PubMed ID: 11210174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors.
    Gong H; Kovar JL; Cheung L; Rosenthal EL; Olive DM
    Cancer Biol Ther; 2014 Feb; 15(2):185-93. PubMed ID: 24100437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of humanized single-chain fragment variable immunotherapeutic against EGFR variant III using baculovirus expression system and in vitro validation.
    Xavier S; Gopi Mohan C; Nair S; Menon KN; Vijayachandran LS
    Int J Biol Macromol; 2019 Mar; 124():17-24. PubMed ID: 30471391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The extracellular domain of the epidermal growth factor receptor. Studies on the affinity and stoichiometry of binding, receptor dimerization and a binding-domain mutant.
    Brown PM; Debanne MT; Grothe S; Bergsma D; Caron M; Kay C; O'Connor-McCourt MD
    Eur J Biochem; 1994 Oct; 225(1):223-33. PubMed ID: 7925442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv.
    Kuan CT; Wikstrand CJ; Archer G; Beers R; Pastan I; Zalutsky MR; Bigner DD
    Int J Cancer; 2000 Dec; 88(6):962-9. PubMed ID: 11093822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.